Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Nimotuzumab + SHR-1210
Sponsor:   The First Affiliated Hospital of Zhengzhou University
Not yet recruiting

https://ift.tt/2EiiWGG